Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains
暂无分享,去创建一个
[1] Z. Jia,et al. A Ca2+ Switch Aligns the Active Site of Calpain , 2002, Cell.
[2] J. Beckmann,et al. Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A). , 2007, Biochimica et biophysica acta.
[3] Z. Jia,et al. Crystal structure of a micro-like calpain reveals a partially activated conformation with low Ca2+ requirement. , 2003, Structure.
[4] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[5] D. McRee,et al. A visual protein crystallographic software system for X11/Xview , 1992 .
[6] Z. Jia,et al. Ca(2+)-induced structural changes in rat m-calpain revealed by partial proteolysis. , 2001, Biochimica et biophysica acta.
[7] H. Sambrook. Molecular cloning : a laboratory manual. Cold Spring Harbor, NY , 1989 .
[8] M. Cygler,et al. Roles of individual EF-hands in the activation of m-calpain by calcium. , 2000, The Biochemical journal.
[9] Ming Liu,et al. Calpain in the CNS: From Synaptic Function to Neurotoxicity , 2008, Science Signaling.
[10] Sarah Dennison,et al. Calpains and Their Multiple Roles in Diabetes Mellitus , 2006, Annals of the New York Academy of Sciences.
[11] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[12] M. Cygler,et al. Structure of a calpain Ca2+-binding domain reveals a novel EF-hand and Ca2+-induced conformational changes , 1997, Nature Structural Biology.
[13] H. Sorimachi,et al. Structure, activation, and biology of calpain. , 2004, Diabetes.
[14] F. Mackenzie,et al. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition. , 2007, Journal of molecular biology.
[15] R. Huber,et al. Structural basis of the endoproteinase-protein inhibitor interaction. , 2000, Biochimica et biophysica acta.
[16] Z. Jia,et al. Crystal structure of calpain reveals the structural basis for Ca2+‐dependent protease activity and a novel mode of enzyme activation , 1999, The EMBO journal.
[17] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[18] Anna Huttenlocher,et al. Regulating cell migration: calpains make the cut , 2005, Journal of Cell Science.
[19] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[20] Kevin K. W Wang,et al. Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.
[21] R. Kiss,et al. Calcium‐induced tripartite binding of intrinsically disordered calpastatin to its cognate enzyme, calpain , 2008, FEBS letters.
[22] W. Bode,et al. Flexibility Analysis and Structure Comparison of Two Crystal Forms of Calcium-Free Human m-Calpain , 2002, Biological chemistry.
[23] M. Bogyo,et al. Development of Calpain-specific Inactivators by Screening of Positional Scanning Epoxide Libraries* , 2007, Journal of Biological Chemistry.
[24] Robert C. Wolpert,et al. A Review of the , 1985 .
[25] P. Davies,et al. Recombinant calpain II: improved expression systems and production of a C105A active-site mutant for crystallography. , 1995, Protein engineering.
[26] Bruce A Johnson,et al. Using NMRView to visualize and analyze the NMR spectra of macromolecules. , 2004, Methods in molecular biology.
[27] D. E. Goll,et al. Interaction of calpastatin with calpain: a review , 2004, Biological chemistry.
[28] F. Morón,et al. The therapeutic potential of the calpain family: new aspects. , 2006, Drug discovery today.
[29] J. Beckmann,et al. Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain. , 2001, Biophysical journal.
[30] R. Campbell,et al. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. , 2004, Journal of molecular biology.
[31] Z. Jia,et al. Calpain silencing by a reversible intrinsic mechanism , 2003, Nature Structural Biology.
[32] R. Campbell,et al. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin , 2008, Nature.
[33] J. Anagli,et al. Structural Determinants of the Calpain Inhibitory Activity of Calpastatin Peptide B27-WT* , 2003, The Journal of Biological Chemistry.
[34] G N Murshudov,et al. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.
[35] G. Lin,et al. A structural model for the inhibition of calpain by calpastatin: crystal structures of the native domain VI of calpain and its complexes with calpastatin peptide and a small molecule inhibitor. , 2003, Journal of molecular biology.
[36] L. DeLucas,et al. Crystal structure of calcium bound domain VI of calpain at 1.9 Å resolution and its role in enzyme assembly, regulation, and inhibitor binding , 1997, Nature Structural Biology.
[37] P. Davies,et al. Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions. , 2005, The Journal of biological chemistry.
[38] R. Huber,et al. The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[39] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.